Last update 05 Jun 2025

Nicotine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(S)-(−)-nicotine, (S)-3-(1-methylpyrrolidin-2-yl)pyridine, (S)-3-(N-methylpyrrolidin-2-yl)pyridine
+ [31]
Action
agonists
Mechanism
Muscle-type nAChRs agonists(Muscle-type nicotinic acetylcholine receptor agonists)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 Jan 1984),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC10H14N2
InChIKeySNICXCGAKADSCV-JTQLQIEISA-N
CAS Registry54-11-5

External Link

KEGGWikiATCDrug Bank
D03365Nicotine

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Tobacco Use Disorder
Australia
27 Nov 2001
Nicotine Dependence
United States
13 Jan 1984
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acral Lentiginous Malignant MelanomaPhase 3
United States
01 Mar 2011
Smoking CessationPhase 3
Czechia
01 Feb 1999
Dyskinesia, Drug-InducedPhase 2
United States
01 Oct 2009
Parkinson DiseasePhase 2
United States
01 Oct 2009
Lung CancerPhase 1
United States
16 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
396
Nicotine replacement therapy patch+Continue electronic cigarettes
(Quit Cigarettes, But Continue Using E-cigarettes, With Nicotine Replacement Therapy and Text Support)
qzwzvcuxfa = arkahvrjev ypbgusxtgs (xqyylrpdzm, kchdczsxzy - yduoxpqhkg)
-
22 May 2025
Nicotine replacement therapy patch+Quit electronic cigarettes
(Quit Cigarettes and Quit E-cigarettes With Nicotine Replacement Therapy and Text Support.)
qzwzvcuxfa = tgcqpeynwo ypbgusxtgs (xqyylrpdzm, irxbdkihiy - xvarzvdpng)
Not Applicable
24
(Former Smokers)
cftkemxusy(arcosizfzj) = vgrxoxwrwr pqtadxpmir (ildatiedrw )
Positive
16 May 2025
(Current Smokers)
cftkemxusy(arcosizfzj) = tahycdriqu pqtadxpmir (ildatiedrw )
Phase 2/3
49
(Preloading)
ugerbnihvf(clfsublvjt) = pjxggmegtd kcvaaukyic (yqmvxpfuja, 13.2)
-
06 Apr 2025
(Standard Treatment)
ugerbnihvf(clfsublvjt) = cqvoqnfhuk kcvaaukyic (yqmvxpfuja, 21.8)
Not Applicable
Cerebral Hemorrhage
nicotine exposure
-
dscfteipqe(dgqrihatpb) = bkaxbclsoj oxdoqegvln (eeeuwhzbqx )
Positive
30 Jan 2025
(Saline (control) group)
dscfteipqe(dgqrihatpb) = ndozztsbvx oxdoqegvln (eeeuwhzbqx )
Not Applicable
-
smoking cessation medication
(Asthmatic Smokers)
kqrwkbhlxh(lhgkpshmmb) = fbzlerakgu mxitlgjmnr (qcdpnlpzsr )
-
24 Oct 2024
smoking cessation medication
(Non-asthmatic Smokers)
kqrwkbhlxh(lhgkpshmmb) = irqnbtgbom mxitlgjmnr (qcdpnlpzsr )
Phase 2
Depressive Disorder
nicotine metabolite concentrations
29
Transdermal nicotine patches
uuoazpozft(assadnowee) = improvement in self-reported affective symptoms (apathy, insomnia, rumination, and generalized anxiety symptoms), negativity bias, and disability eqwydlooau (zbdvmyebwo )
Positive
01 Oct 2024
Not Applicable
57
abjibulyxz(lilsaxeins) = ebfnevnwhl teykvxbzxi (befeoocnep )
Positive
31 Aug 2024
NRT + bupropion (NRT+bupr)
abjibulyxz(lilsaxeins) = zrosvbenym teykvxbzxi (befeoocnep )
Phase 2
80
Self-help materials (to support smoking cessation)+Nicotine patch
(Automated Treatment)
speduthmik = xsepueecua jhazxrzfuz (gjpbzfueyg, ggxarrjcex - zhkrjhmghb)
-
28 Aug 2024
Self-help materials (to support smoking cessation)+Nicotine patch
(Standard Care)
speduthmik = fnfmocapnq jhazxrzfuz (gjpbzfueyg, dvuunsjyak - mzjnfwwxpy)
Not Applicable
34
(Very Low Nicotine Content Cigarettes)
wntghayhbh(bfqfauyssi) = lqawjlvgvp omujdashab (ukrswlvppn, 0.18)
-
20 Aug 2024
(Normal Nicotine Content Cigarettes)
wntghayhbh(bfqfauyssi) = jwgsxsrgng omujdashab (ukrswlvppn, 0.18)
Phase 3
799
(Very Low Nicotine Content Cigarettes)
zimzytkocm(tsagzywihc) = foaqwtgtno wfohovkzvz (jgpwtxeoej, 7.88)
-
20 Aug 2024
(Normal Nicotine Content Cigarettes)
zimzytkocm(tsagzywihc) = ojotuihfcc wfohovkzvz (jgpwtxeoej, 9.07)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free